Novo Nordisk's Wegovy Pill Wins First European Approval for Oral Weight Loss Drug
The European Commission has approved Novo Nordisk's Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, to be used alongside diet and exercise. This marks the first oral GLP-1 receptor agonist approved for weight management across all EU member states. The decision follows a positive opinion from the EMA's CHMP in May 2026 and is supported by the OASIS 4 clinical trial, which showed approximately 17% weight loss in participants versus 3% for placebo. About one-third of treated patients achieved 20% or greater weight loss. The safety profile was consistent with the injectable version. This is the fifth regulatory approval for the Wegovy pill, following authorizations in the US, UK, UAE, and Bahrain. Novo Nordisk plans to introduce the treatment in additional countries during the second half of 2026.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection